Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer

Tonyali, Onder; Benekli, Mustafa; Berk, Veli; Coskun, UĞUR; ÖZKAN, METİN; Yildiz, Ramazan; Ucgul, Emel; Sevinc, Alper; Uncu, Dogan; Demirci, Umut; Buyukberber, Suleyman

doi:10.1007/s00432-013-1409-1

Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer

Atıf İçin Kopyala

Tonyali O., Benekli M., Berk V., Coskun U., ÖZKAN M., Yildiz R., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.139, sa.6, ss.981-986, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 139 Sayı: 6
Basım Tarihi: 2013
Doi Numarası: 10.1007/s00432-013-1409-1
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.981-986
Anahtar Kelimeler: Chemotherapy, Breast cancer, Metastasis, HER2, RANDOMIZED PHASE-III, MONOCLONAL-ANTIBODY, AMPLIFICATION, THERAPY, TRIAL, CHEMOTHERAPY, MULTICENTER, COMBINATION, DOCETAXEL, SAFETY
Gazi Üniversitesi Adresli: Evet

Özet

Combinations of trastuzumab with paclitaxel or capecitabine are effective therapies in human epidermal growth factor 2 (HER2)-positive metastatic breast cancer (MBC). This retrospective study evaluated the efficacy and toxicity of trastuzumab and paclitaxel plus capecitabine in the first-line therapy for patients with HER2-positive MBC.